Table 2.
Survival Benefits From the FDA-Approved Nanomedicines To Date*
| Generic Drug | Trade name (s) | Indication | Benefit | |||
|---|---|---|---|---|---|---|
| Pegylated liposomal doxorubicin | Doxil®and Caelyx® | HIV-related Kaposi's sarcoma | No statistically significant change in overall survival (23 weeks) vs. doxorubicin, bleomycin and vincristine treatment (22.3 weeks) for HIV-related Kaposi's sarcoma | |||
| Metastatic ovarian cancer | Statistically significant overall survival improvement (108 weeks, P= 0.008) vs. topotecan treatment (71.1 weeks) for platinum-sensitive patients with ovarian cancer | |||||
| Metastatic breast cancer | No statistically significant overall survival change (84 weeks) vs. conventional doxorubicin (88 weeks) for breast cancer patients receiving first-line therapy | |||||
| Liposomal daunorubicin | DaunoXome® | HIV-related Kaposi's sarcoma | No statistically significant overall survival change (52.7 weeks) vs. doxorubicin, bleomycin, vincristine treatment (48.9 weeks) | |||
| Poly (styren-co- maleic acid) conjugated naocarzinostatin | SMANCS® | Liver cancer, renal cancer | Approved 1993 in Japan. Far more effective when the EPR is enhanced by increasing the blood pressure in difficult- to-treat tumors including metastatic liver cancer, cancers of pancreas, gallbladder, etc Liver cancer: 5 year survival |
|||
| 1 seg.+ | > | 2 seg | ||||
| Child A | > 90 % | ~ | >50% | |||
| Child B | 40% | 30% | ||||
| Five year survival (%) based on the liver function (cirrhosis) by Child classification, and intrahepatic+ metastasis | ||||||
| Albumin-bound paclitaxel | Abraxane® | Metastatic cancer breast | Statistically significant overall survival change (56.4 weeks, P= 0.024) vs. polyethoxylated castor oil-based paclitaxel treatment (46.7 weeks) for patients receiving second-line treatment | |||
*
The polymeric platform methoxy PEG-poly(D,L-lactide) taxol with the trade name Genexol-PM (Sanayang Co., Seoul, Korea) has been approved in Korea for the treatment of metastatic breast cancer.
Adapted from: 14 Jain, R. K. & Stylianopoulos, T., Nat. Rev. Clin. Oncol. (2010) 7, 653; SMANCS data in the table were provided by prof. Hiroshi Maeda.